GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
27.53
-1.18 (-4.11%)
At close: Jul 20, 2026, 4:00 PM EDT
27.94
+0.41 (1.49%)
Pre-market: Jul 21, 2026, 5:27 AM EDT
GH Research Market Cap
GH Research has a market cap or net worth of $1.89 billion as of July 21, 2026. Its market cap has increased by 73.31% in one year.
Market Cap
1.89B
Enterprise Value
1.62B
1-Year Change
73.31%
Ranking
Category
Stock Price
$27.53
ChartMarket Cap Chart
Since the IPO on June 25, 2021, GH Research's market cap has increased from $808.33M to $1.89B, an increase of 133.67%. That is a compound annual growth rate of 18.22%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 20, 2026 | 1.89B | 139.76% |
| Dec 31, 2025 | 787.77M | 116.30% |
| Dec 31, 2024 | 364.20M | 20.71% |
| Dec 29, 2023 | 301.72M | -40.33% |
| Dec 30, 2022 | 505.64M | -58.34% |
| Dec 31, 2021 | 1.21B | 50.14% |
| Jun 25, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Syndax Pharmaceuticals | 2.02B |
| Nuvation Bio | 2.02B |
| ADMA Biologics | 2.02B |
| Viridian Therapeutics | 1.99B |
| AbCellera Biologics | 1.97B |
| Ocular Therapeutix | 1.96B |
| Lakefront Biotherapeutics NV | 1.96B |
| UroGen Pharma | 1.96B |